English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/101452
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorIbáñez, Clara-
dc.contributor.authorSimó, Carolina-
dc.contributor.authorMartín-Álvarez, Pedro J.-
dc.contributor.authorCifuentes, Alejandro-
dc.identifierdoi: 10.1021/ac301243k-
dc.identifierissn: 0003-2700-
dc.identifiere-issn: 1520-6882-
dc.identifier.citationAnalytical Chemistry 84(20): 8532-8540 (2012)-
dc.description.abstractAlzheimer's disease (AD) is the most prevalent form of dementia with an estimated worldwide prevalence of over 30 million people, and its incidence is expected to increase dramatically with an increasing elderly population. Up until now, cerebrospinal fluid (CSF) has been the preferred sample to investigate central nervous system (CNS) disorders since its composition is directly related to metabolite production in the brain. In this work, a nontargeted metabolomic approach based on capillary electrophoresis-mass spectrometry (CE-MS) is developed to examine metabolic differences in CSF samples from subjects with different cognitive status related to AD progression. To do this, CSF samples from 85 subjects were obtained from patients with (i) subjective cognitive impairment (SCI, i.e. control group), (ii) mild cognitive impairment (MCI) which remained stable after a follow-up period of 2 years, (iii) MCI which progressed to AD within a 2-year time after the initial MCI diagnostic and, (iv) diagnosed AD. A prediction model for AD progression using multivariate statistical analysis based on CE-MS metabolomics of CSF samples was obtained using 73 CSF samples. Using our model, we were able to correctly classify 97-100% of the samples in the diagnostic groups. The prediction power was confirmed in a blind small test set of 12 CSF samples, reaching a 83% of diagnostic accuracy. The obtained predictive values were higher than those reported with classical CSF AD biomarkers (Aβ42 and tau) but need to be confirmed in larger samples cohorts. Choline, dimethylarginine, arginine, valine, proline, serine, histidine, creatine, carnitine, and suberylglycine were identified as possible disease progression biomarkers. Our results suggest that CE-MS metabolomics of CSF samples can be a useful tool to predict AD progression. © 2012 American Chemical Society.-
dc.description.sponsorshipThis work was supported by Projects AGL2011-29857-C03-01, Gun och Bertil Stohnes Stiftelse, Karolinska Institute fund for geriatric research, Stiftelsen Gamla Tjanarinnor, Stiftelsen Dementia, Swedish Alzheimer Foundation, Swedish Brain Foundation, and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institute. C.I. thanks the MEC for her FPI fellowship.-
dc.publisherAmerican Chemical Society-
dc.titleToward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics-
dc.description.versionPeer Reviewed-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderKarolinska Institute-
dc.contributor.funderStiftelsen Dementia-
dc.contributor.funderSwedish Brain Foundation-
dc.contributor.funderSwedish Alzheimer Foundation-
Appears in Collections:(CIAL) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.